leukemia

[Nature Medicine] Researchers conducted a Phase I trial in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia to test AUTO3, autologous transduced T cells expressing both anti-CD19 and anti-CD22 chimeric antigen receptors (CARs).

[Cellular & Molecular Immunology] The authors found that posttransplant treatment with the CXCR4 antagonist AMD3100 significantly improved the eradication of leukemia cells in the bone marrow in patient-derived xenograft mice grafted with B cell acute lymphoblastic leukemia cells from multiple patients.

[Blood Advances] The authors adopted CIBERSORTx to estimate the relative fractions of 22 subtypes of immune cells in the bone marrow of 316 myelodysplastic syndrome patients and correlated the results with clinical outcomes.

[Science Advances] Researchers showed that abnormal IL-36 production activated by NF-κB was an essential feature of mouse and human leukemic progenitor cells.

[JCI Insight] Scientists identified a tumor suppressor role of the acetyltransferase p300 in clinically relevant myelodysplastic syndromes models driven by mutations in the epigenetic regulators TET2, ASXL1, and SRSF2.

[Gates Biomanufacturing Facility] The Gates Biomanufacturing Facility signed a continued strategic agreement with Nkarta to manufacture clinical supply of therapeutic Natural Killer cells. As part of this collaboration, GBF will continue to manufacture NKX101, an immunotherapy currently in a Phase I clinical trial for patients with relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.